Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

Phase 2

Terminated

Conditions: Influenza

Interventions: Drug: Placebo
Drug: Baloxavir Marboxil
Drug: Oseltamivir

Registration Number: NCT05170009

Lead Sponsor: Weill Medical College of Cornell University

Brief Summary: This is a randomized, double-blind, placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. Although there are no data about this treatment option currently available, the investigator hypothesizes that combination therapy may be more effective in clearing influenza virus infection and decreasing the rate of emergence of resistant influenza in immunocompromised human hosts.

Detailed Description: This is a randomized double-blind placebo-controlled pilot study of the efficacy and safety of baloxavir in combination with oseltamivir (standard of care) for the treatment of influenza in allogeneic stem cell transplant patients. 30 SCT recipients will take part in the study. Participants with be randomly assigned (1:1) to either baloxavir + oseltamivir or baloxavir-matched placebo +oseltamivir. Before randomization, patients will be stratified by hospitalization status and influenza type A (yes/no).

Patients in the baloxavir combination arm will receive weight-adjusted baloxavir (40 mg for patients weighing \<80 kg and 80 mg for those weighing ≥80 kg) at baseline and at day 4 and day 7. They will also receive oseltamivir 75 mg twice daily for 10 days. Patients in the baloxavir-matched placebo + oseltamivir arm will receive baloxavir-matched placebo at baseline and at day 3 and day 7and oseltamivir 75 mg twice daily for 10 days.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 2

Inclusion Criteria

Adult patients: Signed informed consent by any patient capable of giving consent, or, where the patient is not capable of giving consent, by his or her legal/authorized representative
Age greater than or equal to 18 years at the time of signing the Informed Consent Form/Assent Form
Ability to comply with the study protocol, in the investigator's judgment
Have received allogeneic bone marrow transplant
Tested positive for influenza infection after the onset of symptoms using a polymerase chain reaction (PCR)-based diagnostic assay.
Presence of (a) fever (≥38.0 °C per tympanic or rectal thermometer; ≥ 37.5 °C per axillary, oral or forehead/temporal thermometer) or (b) any influenza symptoms (cough, sore throat, nasal congestion, headache, feverishness or chills, muscle or joint pain, fatigue).
The time interval between the diagnosis of influenza and the pre-dose examinations is 48 hours or less.
For women of childbearing potential: Agreement to remain abstinent (refrain from heterosexual intercourse):
Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 28 days after the last dose of study treatment. Hormonal contraceptive methods must be supplemented by a barrier method. A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state greater than or equal to 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

Exclusion Criteria

Patients who have received more than 48 hours of antiviral treatment for the current influenza infection prior to screening
Patients who have received Baloxavir for the current influenza infection
Known contraindication to neuraminidase inhibitors
Patients weighing < 40 kg
Patients unable to swallow tablets
Patients with known severe renal impairment (estimated glomerular filtration rate < 30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
Patients with any of the following laboratory abnormalities detected within 24 hours prior to or during screening (according to local laboratory reference ranges: ALT or AST level > 5 times the upper limit of normal (ULN) OR ALT or AST > 3 times the ULN and total bilirubin level > 2 times the ULN
Pregnant or breastfeeding, or positive pregnancy test in a predose examination, or intending to become pregnant during the study or within 28 days after the last dose of study treatment
Exposure to an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study
Known hypersensitivity to baloxavir marboxil or the drug product excipients
Known COVID-19 coinfection
Unwilling to undergo nasopharyngeal (NP) swabs as per study schedule

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo and standard of care	Placebo	Placebo-matched Baloxavir Marboxil and standard of care Oseltamivir
Active and standard of care	Oseltamivir	Active Baloxavir Marboxil and standard of care Oseltamivir
Active and standard of care	Baloxavir Marboxil	Active Baloxavir Marboxil and standard of care Oseltamivir
Placebo and standard of care	Oseltamivir	Placebo-matched Baloxavir Marboxil and standard of care Oseltamivir

Primary Outcome Measures

Name	Time	Method
Change of Influenza Viral RNA Loads From Baseline at the End of Treatment as Measured by Quantitative Real Time Polymerase Chain Reaction.	Baseline; Day 10	Influenza viral RNA loads will be measured by quantitative real time polymerase chain reaction.
Between-treatment-arm Difference in the Change of Influenza Viral RNA Loads From Baseline at the End of Treatment as Measured by Quantitative Real Time Polymerase Chain Reaction.	Baseline; Day 10	Influenza viral load will be measured by the quantitative real time polymerase chain reaction.
Between-treatment-arm Difference in the Change of Influenza Viral RNA Loads From Baseline at the End of Treatment as Measured by Influenza Plaque Assay (Replicating Virus).	Baseline; Day 10	Influenza viral load will be measured by the influenza plaque assay.

Secondary Outcome Measures

Name	Time	Method
Change of Influenza Viral RNA Load From Baseline at Day 4 and Day 7 and 10 in Each Treatment Arm	Baseline; Day 4; Day 7; Day 10	Influenza viral RNA load will be measured by quantitative real time polymerase chain reaction.
Difference in Change of Influenza Viral Loads From Baseline at Day 4, 7 and 10 Between the Two Treatment Arms as Measured by Quantitative Real Time Polymerase Chain Reaction	Baseline; Day 4; Day 7; Day 10	Influenza viral RNA load will be measured by quantitative real time polymerase chain reaction.
Change of Influenza Viral Loads From Baseline at Day 4, 7 and 10 as Measured by Influenza Plaque Assay (Replicating Virus) in Each Treatment Arm	Baseline; Day 4; Day 7; Day 10	Influenza viral load will be measured by the influenza plaque assay (replicating virus).
Difference in Change of Influenza Viral Loads From Baseline at Day 4, 7 and 10 Between the Two Treatment Arms as Measured by Influenza Plaque Assay (Replicating Virus)	Baseline; Day 4; Day 7; Day 10	Influenza viral load will be measured by the influenza plaque assay (replicating virus).
Time to Improvement of Individual Influenza Symptoms as Assessed by Patient-reported Outcome Measures on a Single Scale	Baseline to Day 30	Patients will self-assess the severity of 7 influenza-associated symptoms on a 4-point single scale with 0 indicating no symptoms and higher scores indicating mild, moderate, and severe symptoms. Time to improvement of individual influenza symptoms are defined as the time from the start of treatment to the time when each of the influenza symptoms are alleviated, maintained, or improved for a duration of at least 21.5 hours. These are defined as: pre-existing symptoms (cough, fatigue, or muscle/join pain that existed prior to influenza) that were worse at baseline and had improved at least 1 point from baseline; pre-existing symptoms not worse at baseline that maintained baseline severity; and new symptoms that were alleviated, defined as a symptom score of non (0) or mild (1).
Percentage of Patients Who Experience Each Influenza-related Complications: Hospitalization, Death, Sinusitis, Otitis Media, Bronchitis, and Radiologically-confirmed Pneumonia as an Adverse Event After the Initiation of Study Treatment	Day 1 to Day 30	A composite score of multiple measures will be used and calculated by count of patients who experience each influenza-related complications. Adverse events will only include those that are determined to be related to the study drug.
Time to Return to Preinfluenza Health Status	Day 1 to Day 30	Preinfluenza health status will be measured on a score from 0 (worst possible health) to 10 (normal health \[for someone your age and condition\]).
Time to Viral Clearance, as Assessed by Difference in Percentage of Participants Positive by Influenza Plaque Assay at Each Time-point (in Each Treatment Group)	Baseline to Day 30	Time to viral clearance will be assessed by percentage of participants positive by influenza plaque assay at each time-point.
Time to Viral Clearance, as Assessed by Difference in Percentage of Participants Positive by Quantitative Real Time Polymerase Chain Reaction	Baseline to Day 30	Time to viral clearance will be assessed by percentage of participants positive by qPCR at each time-point.
Change of Treatment-emergent Variants of Neuraminidase and Polymerase Known to Confer Antiviral Resistance to Oseltamivir in Each Arm by Direct Next-generation Sequencing Symptoms	Baseline to Day 30	Treatment-emergent variants will be identified using direct next-generation sequencing of a comprehensive panel of genes.
Percentage of Participants With Adverse Events (AEs)	Day 1 to Day 15	Adverse events will only include those that are determined to be related to the study drug and will assess the safety and tolerability of Baloxavir in Combination with SOC treatment.